Recombinant Mouse BTLA Fc Chimera Protein, CF

When Recombinant Mouse HVEM/TNFRSF14 Fc Chimera (Catalog # 2516-HV) is coated at 0.1 μg/mL,Recombinant Mouse BTLA Fc Chimera inhibits the bindingof biotinylated Recombinant Mouse BTLA Fc Chimera with an IC50 of0.3-1 µg/mL

• Reactivity: Mu
• Applications: Binding Activity
• Format: Carrier-Free

Recombinant Mouse BTLA Fc Chimera Protein, CF Summary

• Details of Functionality: Measured in a competitive binding assay. When Recombinant Mouse HVEM/TNFRSF14 Fc Chimera (Catalog # 2516-HV) is immobilized at 0.1 µg/mL (100 µL/well), Recombinant Mouse BTLA Fc Chimera inhibits 50% binding of biotinylated Recombinant Mouse BTLA Fc Chimera (0.2 µg/mL) at the concentration range of 0.3-1 µg/mL.
• Source: Mouse myeloma cell line, NS0-derived mouse BTLA protein
  

  Mouse BTLA Glu30-Gly176 (Lys173Glu) Accession # Q32MV9	IEGRMDP	Mouse IgG2A (Glu98-Lys330)
  N-terminus		C-terminus

• Accession #: Q32MV9
• N-terminal Sequence: Glu30
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: Btla
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Binding Activity
• Theoretical MW: 44 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 60-70 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Mouse BTLA Fc Chimera Protein, CF

• B and T lymphocyte associated
• B and T lymphocyte attenuator
• B- and T-lymphocyte attenuator
• B- and T-lymphocyte-associated protein
• BTLA
• BTLA1
• CD272 antigen
• CD272
• FLJ16065
• MGC129743

Background

B- and T-lymphocyte attenuator (BTLA; CD272) is a 35 kDa type I transmembrane glycoprotein in the CD28 family of T cell co-stimulatory molecules (1-3). Mature mouse BTLA contains a 154 amino acid (aa) extracellular domain (ECD), a 21 aa transmembrane sequence, and a 102 aa cytoplasmic domain. The two ITIM motifs and three Tyr phosphorylation sites in the cytoplasmic tail transmit inhibitory signaling (4-5). The ECD of mouse BTLA shares 51% and 77% aa identity with that of human and rat BTLA, respectively. A splice variant lacking the transmembrane domain has been reported (6). Unlike other CD28 family members, the BTLA Ig domain in the ECD is of the I-type rather than V-type, and BTLA does not form homodimers (7). BTLA is also unusual in its interaction with the TNF superfamily member HVEM rather than with B7 family ligands (8). BTLA is expressed on T cells, B cells, macrophages, dendritic cells, and NK cells (9). Its expression is low in naïve T cells and increases during antigen-specific induction of anergy. In B cells, BTLA expression is highest in mature naïve cells (9). BTLA apparently limits T cell numbers, since its deletion results in over-production of T cells, especially CD8⁺ memory T cells that are hyper-responsive to TCR cross-linking (10). Under the control of ROR gamma t and IL-7, BTLA regulates the homeostasis and inflammatory responses of gamma δT cells (11). The binding of BTLA and HVEM does not preclude the concurrent binding of other HVEM ligands such as LIGHT or Lymphotoxin-alpha (12).

1. Murphy, K.M. et al. (2006) Nat. Rev. Immunol. 6:671.
2. Croft, M. (2005) Trends. Immunol. 26:292.
3. Watanabe, N. et al. (2003) Nat. Immunol. 4:670.
4. Gavrieli, M. et al. (2003) Biochem. Biophys. Res. Commun. 312:1236.
5. Chemnitz, J.M. et al. (2006) J. Immunol. 176:6603.
6. Han, P. et al. (2004) J. Immunol. 172 :5931.
7. Compaan, D.M. et al. (2005) J. Biol. Chem. 280:39553.
8. Sedy, J. R. et al. (2005) Nat. Immunol. 6:90.
9. Hurchla, M.A. et al. (2005) J. Immunol. 174:3377.
10. Krieg, C. et al. (2007) Nat. Immunol. 8:162.
11. Bekiaris, V. et al. (2013) Immunity 39:1082.
12. Cai G and Freeman GJ, (2009) Immunol Rev. 229:244

Publications for BTLA/CD272 (3007-BT)(1)

Publication using 3007-BT

• A Hanson, K Elpek, E Duong, L Shallberg, M Fan, C Johnson, M Wallace, GR Mabry, S Sazinsky, L Pepper, CJ Shu, S Sathyanara, S Zuerndorfe, T Simpson, M Gostissa, M Briskin, D Law, J Michaelson, CJ Harvey ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models PLoS ONE, 2020-09-24;15(9):e0239595. 2020-09-24 [PMID: 32970735] (Bioassay, Human)

Bioinformatics

• Gene Symbol: Btla
• Uniprot:
  • Q32MV9()